NF2 and neoplasm: Bevacizumab (Avastin®), a monoclonal antibody that neutralizes vascular endothelial growth factor (VEGF), is administered off-label to patients with NF2 and progressive VS, with ~36-41% of the patients experiencing durable hearing improvement and reduced tumor volume (22, 23).